Tag - ABEO

Markets

SVB Leerink cuts Abeona Therapeutics to MP; PT to $1 from $5

SVB Leerink downgraded Abeona Therapeutics (NASDAQ:ABEO) to “market perform” from “outperform” and slashed its price target to $1 from $5 after stronger-than-expected data from competitor Krystal Biotech (NASDAQ:KRYS). ...

November 30, 2021

Developments

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) treated the first patient in its Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The trial, being conducted at Stanford...

March 19, 2020

Developments

FDA removes hold on Abeona’s pivotal gene therapy trial

The FDA removed its clinical hold on Abeona Therapeutics’ (NASDAQ:ABEO) Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The hold was removed following...

December 9, 2019

Developments

Abeona reports positive interim data from Phase 1/2 gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) reported positive data from its ongoing Phase 1/2 clinical trial of ABO-102 for the treatment of Sanfilippo syndrome type A (MPS IIIA). Primarily affecting the central nervous system...

July 25, 2019

Developments

FDA accepts Abeona IND for CLN1 disease gene therapy

The FDA has accepted Abeona Therapeutics (NASDAQ:ABEO) IND application for AB-202 for the treatment of CLN1 disease. CLN1 disease, also known as infantile Batten disease, is caused by a mutation in the PPT1 gene. In...

May 21, 2019

Tag - ABEO

SVB Leerink cuts Abeona Therapeutics to MP; PT to $1 from $5

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

FDA removes hold on Abeona’s pivotal gene therapy trial

Abeona reports positive interim data from Phase 1/2 gene therapy trial

FDA accepts Abeona IND for CLN1 disease gene therapy

General

More